Treatment
Obinutuzumab clinical trials
We’re tracking 80 recruiting studies that include Obinutuzumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06978088RecruitingPhase 2
A study of LP-168 and obinutuzumab for CLL/SLL
This trial tests a new combination of two drugs, LP-168 and obinutuzumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease has come back or not responded to previous treatments. It may be an option if you have already tried certain therapies, including a BTK inhibitor or a BCL2 inhibitor.
Cincinnati, OhioAges 18 years+ - NCT06967610RecruitingPhase 2
Pirtobrutinib, venetoclax, and obinutuzumab for recurrent CLL/SLL
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
Houston, TexasAges 18 years+ - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Laguna Hills, CaliforniaAges 18 years+ - NCT06940661RecruitingPhase 2
Obinutuzumab for relapsing vasculitis
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
ParisAges 18 years+ - NCT06793189RecruitingPhase 2
Risk-Adapted Targeted Therapy for Untreated MZL
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Shanghai, ChinaAges 18 years+ - NCT02393157RecruitingPhase 2
Obinutuzumab plus chemotherapy for certain CD20+ relapsed lymphomas
This Phase 2 study tests how well obinutuzumab (an antibody medicine) combined with chemotherapy works for people whose CD20-positive B-cell lymphoma has come back or didn’t respond to initial treatment. It may help by attacking lymphoma cells that carry the CD20 marker.
Valhalla, New YorkAges 3–31 - NCT06561360RecruitingPhase 2
Comparing two treatments for hairy cell leukemia
This study tests whether a combination of targeted drugs (vemurafenib and obinutuzumab) works better than a standard chemo-immunotherapy combination (cladribine and rituximab) for people newly diagnosed with hairy cell leukemia. If you have the BRAF V600E mutation and meet blood count criteria, you may be eligible to join.
Boston, MassachusettsAges 18 years+ - NCT06544785RecruitingPhase 2
Zanubrutinib plus obinutuzumab for untreated CLL or SLL
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
AlicanteAges 18 years+ - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Tucson, ArizonaAges 18 years+ - NCT06357676RecruitingPhase 1/Phase 2
Glofitamab, Ibrutinib and Obinutuzumab for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
Portland, OregonAges 18 years+ - NCT06333262RecruitingPhase 2
Fixed-duration pirtobrutinib and obinutuzumab for untreated CLL
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
Scarborough, MaineAges 18 years+ - NCT06295770RecruitingPhase 2
Obinutuzumab for fibrillary glomerulonephritis
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
Rochester, MinnesotaAges 18 years+ - NCT06186648RecruitingPhase 2
Glofitamab with chemo for Richter syndrome
This trial tests a new drug called glofitamab combined with standard chemo-immunotherapy (rituximab or obinutuzumab plus CHOP) for people with Richter syndrome, an aggressive lymphoma that arises from CLL. The goal is to see if the combination is safe and effective.
AmiensAges 18 years+ - NCT06175000RecruitingPhase 2
Maintenance obinutuzumab for central nervous system lymphoma
This trial tests whether a maintenance drug called obinutuzumab can help prevent relapse in people with primary central nervous system lymphoma (a rare lymphoma in the brain or spine) who have already responded to initial chemotherapy. It is for those who have achieved at least a partial or complete response to their first treatment.
New York, New YorkAges 18 years+ - NCT06108232RecruitingPhase 2
Study of two drugs for untreated follicular lymphoma
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
Houston, TexasAges 18 years+ - NCT05943496RecruitingPhase 1
Tafasitamab plus acalabrutinib and obinutuzumab for untreated CLL/SLL
This Phase 1 study tests a new combination of medicines to treat people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has not been treated before and needs therapy. It aims to shrink the disease and control it safely in this early testing stage.
Portland, OregonAges 18 years+ - NCT06054776RecruitingPhase 2
Acalabrutinib, obinutuzumab, and glofitamab for mantle cell lymphoma
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
Duarte, CaliforniaAges 18 years+ - NCT05929222RecruitingPhase 3
Radiation with or without an antibody for early follicular lymphoma
This study tests whether adding obinutuzumab (an antibody medicine) to local radiation works better than radiation alone in early-stage follicular lymphoma. It aims to improve disease control while keeping treatment safe.
Sassuolo, Modena (MO)Ages 18 years+ - NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT05536349RecruitingPhase 2
Testing three drug combo for untreated CLL or CLL-related cancer
This Phase 2 study tests pirtobrutinib plus venetoclax plus obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL) or CLL-related Richter transformation (RT). The goal is to see if this “triplet” combination works better and is safe enough to control the disease.
Houston, TexasAges 18 years+ - NCT05336812RecruitingPhase 2
Acalabrutinib with venetoclax or obinutuzumab for untreated CLL
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
Columbus, OhioAges 18 years+ - NCT04895436RecruitingPhase 2
Oral venetoclax plus IV obinutuzumab after prior CLL treatment
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
La Jolla, CaliforniaAges 18 years+ - NCT04883437RecruitingPhase 2
Acalabrutinib plus obinutuzumab for slow-growing lymphoma
This Phase 2 study tests two medicines together—acalabrutinib and obinutuzumab—in people with previously untreated, slow-growing B-cell lymphomas. It aims to shrink the lymphoma and improve disease control, especially when tumor burden is low or when standard first treatments aren’t suitable.
Atlanta, GeorgiaAges 18 years+ - NCT04169737RecruitingPhase 2
Acalabrutinib and venetoclax for high-risk CLL or SLL
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
Houston, TexasAges 18 years+
Common questions
- Are there clinical trials studying Obinutuzumab?
- Yes. Clin2 currently lists 80 recruiting studies that include Obinutuzumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Obinutuzumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Obinutuzumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Obinutuzumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.